_:nb0bcc634c9404fd092e412ef235e184fxb0
<http://schema.org/description>
"- Submissions supported by two Phase 3 studies in patients with active psoriatic arthritis in which SKYRIZI demonstrated improved skin and joint symptoms and physical function, with a greater proportion of patients achieving minimal disease activity versus placebo[1]- In the pivotal studies, patients treated with SKYRIZI received four maintenance doses a year, following two initiation doses[1]- Psoriatic arthritis is a systemic inflammatory disease that impacts the skin and joints, affecting approximately 30 percent of patients with psoriasis[2-5]- AbbVie remains committed to working with regulatory authorities to bring SKYRIZI to more patients living with immune-mediated diseasesAbbVie&nbsp;(NYSE: ABBV) today announced that it has submitted applications seeking approval for SKYRIZI®&nb..."
<https://www.pharmiweb.com/press-release/2021-04-08/abbvie-submits-regulatory-applications-for-skyrizi-risankizumab-in-psoriatic-arthritis-to-fda-and-ema>